BSE · 524414
Norris Medicines Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹6 Cr with net profit ₹-1 Cr — a -21.04% net margin, versus -20.95% the period before.
Shareholding
As of 2026-06-30
- Promoter34.01%
- Public65.92%
- DII0.07%
25,777 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.64× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0 · LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #89 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,41,478 Cr | 34.94 | 5.29 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,631 Cr | 22.86 | 4.12 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,353 Cr | 30.84 | 3.2 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,06,387 Cr | 97.28 | 20.09 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹97,282 Cr | 30.19 | 2.55 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹96,652 Cr | 25.56 | 2.54 | 9.25% | 10.7% |
| Lupin Limited | ₹95,797 Cr | 16.08 | 4.27 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹94,174 Cr | 44.14 | 5.77 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,276 Cr | 21.88 | 6.49 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,713 Cr | 87.27 | 1.85 | 1.14% | 2.89% |
| Norris Medicines Ltd.(this company) | ₹15 Cr | — | 0 | 1.85% | -4.87% |
AI analysis
AI-generated · google/gemini-2.5-flashNorris Medicines Ltd. is listed with a market capitalization of Rs 16 Cr. The company reported revenue of Rs 5.88 Cr and a negative profit margin of -344%.
Positives
- +The company's debt-to-equity ratio is 0, indicating no debt.
- +The return on equity (ROE) of 185.2% indicates efficient use of shareholder capital.
- +The company has no pledged shares by its promoters, with promoter pledge at 0%.
Negatives
- −The profit margin is -344%, indicating substantial losses.
- −The company has reported negative EPS, at -1.24 for Mar 2025, showing consistent losses.
- −Revenue has declined from Rs 12.30 Cr in Mar 2021 to Rs 5.88 Cr in Mar 2025.
- −The book value is negative, at -15.07, suggesting liabilities exceed assets.
- −The company is under regulatory surveillance, specifically 'GSM' and 'LT-ASM' measures, which indicates potential risks.
Financial performance
Norris Medicines Ltd. reported revenue of Rs 5.88 Cr. The company's revenue has been inconsistent, falling from Rs 12.30 Cr in Mar 2021 to Rs 5.66 Cr in Mar 2024, before rising slightly to Rs 5.88 Cr in Mar 2025. Net profit has been consistently negative, with a loss of Rs -1.24 Cr in Mar 2025.
Profitability & returns
The company's profit margin stands at -344%, indicating significant losses relative to revenue. Return on capital employed (ROCE) is 3.44%, while Return on Equity (ROE) is 185.2%. The Earnings Per Share (EPS) for Mar 2025 was -1.24, continuing a trend of negative EPS over the last five years.
Balance sheet
Norris Medicines Ltd. has a negative book value of -15.07. The debt-to-equity ratio is 0, indicating an absence of debt. Quarterly results show net profits ranging from -0.72 Cr in Sept 2025 to 0.70 Cr in Dec 2025, and 0.05 Cr in Mar 2026.
Ownership & pledges
Public shareholding is 65.92%, with DIIs holding 0.07%. There are no pledged shares by promoters. The number of shareholders is 25,777.
Regulatory & surveillance
Norris Medicines Ltd. is currently under surveillance. It has been classified under 'GSM' and 'LT-ASM' measures, indicating increased scrutiny due to factors such as price variation, volume variation, or financial health.
Data as of — price: 2026-09-12 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.